Europe Automated Breast Ultrasound Systems Industry Forecast About Next 6 Years

Graphical Research  |

Europe automated breast ultrasound systems market growth is spurred by the rising awareness about breast cancer screening coupled with growing number of initiatives. Breast cancer screening program (BCSP) was extensively implemented for early breast cancer screening in Russia. The program offers screening at 2-year intervals to women between 40 to 60 years of age. Such initiatives are estimated to impel the adoption of ABUS in recent years.

Europe Automated Breast Ultrasound Systems (ABUS) Market is estimated to reach USD 328 Million by 2024. Restricted capability of mammography systems to diagnose breast cancer in dense breast tissues will positively impact ABUS business growth. ABUS assists in detecting small tumors at early stage of breast cancer that can significantly reduce treatment cost due to early diagnosis. Various studies have proved superlative detection rate of ABUS over mammography system. Thus, superior screening and detection rate over mammography system will drive demand for automated imaging modalities in foreseeable years.

Automated breast ultrasound system segment held significant market size of USD 51.1 million in 2017. Higher detection rate of breast cancer than mammography systems increases the customer preference for ABUS. In addition, enhanced or large field of view of breast and decreased time for generating breast images contribute to the benefits, that will result into segmental expansion over the coming years.

Diagnostic imaging centers segment will grow at rapid pace of 13.0% CAGR. Growing healthcare spending on cancer treatment for patients in Europe will offer attractive opportunity for segmental expansion. Implementation of national screening program in the region will further stimulate segmental share in foreseeable years.

Few of the established market players in Europe automated breast ultrasound systems market are GE Healthcare, Hitachi Ltd., Koninklijke Philips N.V., Siemens AG, SonoCine Inc., and Theraclion. Industry players are concentrating efforts on strategic alliances such as agreements, mergers and acquisitions for fortifying market presence and for capturing profits. For instance, in July 2016, Royal Philips strategically partnered with Andalusian Health Service, Spain. Partnership with various hospitals ensures installation, integration, maintenance, and updates of medical technologies provided by the firm in order to achieve optimal delivery of care.

DISCLOSURE: Graphical Research reports have been constructed taking into consideration each regional market as an independent industry, since each country-level industry is governed by a different set of dynamics, consumer behavior and regulatory landscape. In addition to a high degree of accuracy, this approach also enables us to better analyze the industry scenario and offer targeted business intelligence.


The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.